Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Pugh

Showing results (181-190 of 224) with videos related to

Pageof 23
Sort By:
International Journal of Radiation Oncology, Biology, Physics|February 3, 2023
Neighborhood Deprivation and Rurality Associated With Patient-Reported Outcomes and Survival in Men With Prostate Cancer in NRG Oncology RTOG 0415Jinbing Bai, Stephanie L Pugh, Ronald Eldridge, et al.
European Urology|January 29, 2023
Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised TrialLoren K Mell, Stephanie L Pugh, Christopher U Jones, et al.
International Journal of Radiation Oncology, Biology, Physics|January 2, 2023
Five-Year Patient-Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate CancerHimanshu R Lukka, Snehal Deshmukh, Deborah W Bruner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2020
Improvement in Patient-Reported Outcomes With Intensity-Modulated Radiotherapy (RT) Compared With Standard RT: A Report From the NRG Oncology RTOG 1203 StudyAnamaria R Yeung, Stephanie L Pugh, Ann H Klopp, et al.
JAMA Oncology|March 14, 2024
Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical TrialMark K Buyyounouski, Stephanie L Pugh, Ronald C Chen, et al.
European Urology Oncology|November 14, 2024
Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Phase 3 TrialsKrishnan R Patel, Paul L Nguyen, James A Proudfoot, et al.
Gynecologic Oncology|May 21, 2019
Expanded validation of the EPIC bowel and urinary domains for use in women with gynecologic cancer undergoing postoperative radiotherapyKaren M Gil, Stephanie L Pugh, Ann H Klopp, et al.
Advances in Radiation Oncology|April 20, 2026
The Association of p27 With Prostate Cancer Outcomes: A Secondary Analysis of NRG/RTOG 8610 and 9202Krishnan R Patel, Stephanie L Pugh, Jeffry P Simko, et al.
JCO Oncology Advances|May 15, 2025
Patient-Reported Outcomes During Pelvic Radiation Therapy: A Secondary Analysis on Sexual Function From NRG-RTOG 1203Kelsey L Corrigan, Rebecca Paulus, Ann H Klopp, et al.
Neuro-Oncology Advances|October 27, 2022
Germline polymorphisms in <i>MGMT</i> associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825Michael E Scheurer, Renke Zhou, Mark R Gilbert, et al.
Pageof 23

Showing results (181-190 of 224) with videos related to

Sort By:
Pageof 23
International Journal of Radiation Oncology, Biology, Physics|February 3, 2023
Neighborhood Deprivation and Rurality Associated With Patient-Reported Outcomes and Survival in Men With Prostate Cancer in NRG Oncology RTOG 0415Jinbing Bai, Stephanie L Pugh, Ronald Eldridge, et al.
European Urology|January 29, 2023
Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised TrialLoren K Mell, Stephanie L Pugh, Christopher U Jones, et al.
International Journal of Radiation Oncology, Biology, Physics|January 2, 2023
Five-Year Patient-Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate CancerHimanshu R Lukka, Snehal Deshmukh, Deborah W Bruner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2020
Improvement in Patient-Reported Outcomes With Intensity-Modulated Radiotherapy (RT) Compared With Standard RT: A Report From the NRG Oncology RTOG 1203 StudyAnamaria R Yeung, Stephanie L Pugh, Ann H Klopp, et al.
JAMA Oncology|March 14, 2024
Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical TrialMark K Buyyounouski, Stephanie L Pugh, Ronald C Chen, et al.
European Urology Oncology|November 14, 2024
Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Phase 3 TrialsKrishnan R Patel, Paul L Nguyen, James A Proudfoot, et al.
Gynecologic Oncology|May 21, 2019
Expanded validation of the EPIC bowel and urinary domains for use in women with gynecologic cancer undergoing postoperative radiotherapyKaren M Gil, Stephanie L Pugh, Ann H Klopp, et al.
Advances in Radiation Oncology|April 20, 2026
The Association of p27 With Prostate Cancer Outcomes: A Secondary Analysis of NRG/RTOG 8610 and 9202Krishnan R Patel, Stephanie L Pugh, Jeffry P Simko, et al.
JCO Oncology Advances|May 15, 2025
Patient-Reported Outcomes During Pelvic Radiation Therapy: A Secondary Analysis on Sexual Function From NRG-RTOG 1203Kelsey L Corrigan, Rebecca Paulus, Ann H Klopp, et al.
Neuro-Oncology Advances|October 27, 2022
Germline polymorphisms in <i>MGMT</i> associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825Michael E Scheurer, Renke Zhou, Mark R Gilbert, et al.
Pageof 23